Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma

NCT01071837 is registered in ClinicalTrials.gov with Apogenix GmbH as lead sponsor.

NCT NCT01071837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
Lead sponsor
Apogenix GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
October 31, 2014
Enrollment
84 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme